Equity Profile

CRNX

Crinetics Pharmaceuticals, Inc.

Health CarePharmaceuticals$9.0B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for endocrine diseases and disorders....

Key Metrics to Watch

EPS

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

$-1.06

Revenue

Revenue figures help gauge the company's sales performance and market demand for its products.

$16M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRNX Q2-2026 Earnings Preview

Context

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for endocrine diseases and disorders. With a market cap of $9 billion, it plays a significant role in the pharmaceutical industry, particularly in addressing unmet medical needs in hormone-related conditions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

+1.78%

Last Quarter Recap

In Q1-2026, Crinetics reported an EPS of $-1.23, slightly missing estimates. The stock reacted positively, gaining 4.27% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Crinetics to report a loss of $1.06 per share on $16 million in revenue for Q2-2026. The market is closely watching for any signs of improvement in financial performance.

Bull Case

If Crinetics can exceed the EPS estimate and show strong revenue growth, it could signal a turnaround in their financial health, leading to increased investor confidence.

Bear Case

Conversely, if the company fails to meet expectations again, it may raise concerns about its ability to execute on its business strategy, potentially leading to a decline in stock price.

Key Metrics to Watch

EPS

$-1.06

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

Revenue

$16M

Revenue figures help gauge the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Crinetics achieve an EPS closer to the consensus estimate of $-1.06?

A smaller loss than expected could indicate improving operational efficiency and boost investor confidence.

What are the revenue figures for this quarter, and how do they compare to the $16 million consensus?

Revenue performance is critical to understanding market demand for Crinetics' products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Crinetics to improve its financial performance this quarter, given recent positive developments in their product pipeline.

Supporting Evidence

The stock has shown resilience with a positive reaction following past earnings misses, suggesting underlying strength.

Options pricing indicates a significant expected move, which may reflect investor anticipation of better-than-expected results.

Key Risk

If the revenue exceeds $16 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal in determining whether Crinetics can stabilize its financials and regain investor trust.

Bull Confirmed If

An EPS of $-1.06 or better, along with revenue exceeding $16 million, would confirm a positive outlook.

Bear Confirmed If

An EPS worse than $-1.08 and revenue below $16 million would signal ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±17.74%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±17.7% while CRNX has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

59.7%

Calls (600)P/C Ratio: 0.92Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Crinetics beats expectations, history suggests a potential stock increase of around 1.42%, confirming a positive trend.

In-Line / Cautious

A result in line with expectations may lead to a muted response, as the market assesses future guidance.

Miss

If the company misses estimates, history indicates a potential decline of about 1.90%, raising concerns about its financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on any new product developments or clinical trial results.
2Management's outlook on revenue growth and market demand.
3Any updates on partnerships or collaborations that could enhance product distribution.
4Insights into cost management strategies and operational efficiencies.
5Guidance on future earnings expectations and strategic goals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for endocrine diseases and disorders....

Key Metrics to Watch

EPS

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

$-1.06

Revenue

Revenue figures help gauge the company's sales performance and market demand for its products.

$16M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRNX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

+1.78%

Last Quarter Recap

In Q1-2026, Crinetics reported an EPS of $-1.23, slightly missing estimates. The stock reacted positively, gaining 4.27% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Crinetics to report a loss of $1.06 per share on $16 million in revenue for Q2-2026. The market is closely watching for any signs of improvement in financial performance.

Bull Case

If Crinetics can exceed the EPS estimate and show strong revenue growth, it could signal a turnaround in their financial health, leading to increased investor confidence.

Bear Case

Conversely, if the company fails to meet expectations again, it may raise concerns about its ability to execute on its business strategy, potentially leading to a decline in stock price.

Key Metrics to Watch

EPS

$-1.06

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

Revenue

$16M

Revenue figures help gauge the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Crinetics achieve an EPS closer to the consensus estimate of $-1.06?

A smaller loss than expected could indicate improving operational efficiency and boost investor confidence.

What are the revenue figures for this quarter, and how do they compare to the $16 million consensus?

Revenue performance is critical to understanding market demand for Crinetics' products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Crinetics to improve its financial performance this quarter, given recent positive developments in their product pipeline.

Supporting Evidence

The stock has shown resilience with a positive reaction following past earnings misses, suggesting underlying strength.

Options pricing indicates a significant expected move, which may reflect investor anticipation of better-than-expected results.

Key Risk

If the revenue exceeds $16 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal in determining whether Crinetics can stabilize its financials and regain investor trust.

Bull Confirmed If

An EPS of $-1.06 or better, along with revenue exceeding $16 million, would confirm a positive outlook.

Bear Confirmed If

An EPS worse than $-1.08 and revenue below $16 million would signal ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±17.74%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±17.7% while CRNX has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

59.7%

Calls (600)P/C Ratio: 0.92Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Crinetics beats expectations, history suggests a potential stock increase of around 1.42%, confirming a positive trend.

In-Line / Cautious

A result in line with expectations may lead to a muted response, as the market assesses future guidance.

Miss

If the company misses estimates, history indicates a potential decline of about 1.90%, raising concerns about its financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on any new product developments or clinical trial results.
2Management's outlook on revenue growth and market demand.
3Any updates on partnerships or collaborations that could enhance product distribution.
4Insights into cost management strategies and operational efficiencies.
5Guidance on future earnings expectations and strategic goals.